MARKET

ARMP

ARMP

Armata Pharmaceuticals Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

3.410
+0.040
+1.19%
Closed 16:00 01/22 EST
OPEN
3.370
PREV CLOSE
3.370
HIGH
3.430
LOW
3.339
VOLUME
5.48K
TURNOVER
--
52 WEEK HIGH
6.92
52 WEEK LOW
2.520
MARKET CAP
63.77M
P/E (TTM)
-2.2190
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
, /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today ...
PR Newswire - PRF · 12/09/2020 12:30
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Robi...
PR Newswire · 12/09/2020 12:30
Arm CEO expects regulators to ‘take a good look’ at the Nvidia deal
Simon Segars, the chief executive of Arm, said he expects regulators to "take a good look" at the company's deal with U.S. chipmaker Nvidia.
CNBC.com · 12/02/2020 20:56
Arm CEO expects regulators to ‘take a good look’ at the Nvidia deal
Simon Segars, the chief executive of Arm, said he expects regulators to "take a good look" at the company's deal with U.S. chipmaker Nvidia.
CNBC.com · 12/02/2020 11:01
Chipmaker Nvidia could join tech's trillion-dollar club if Arm deal wins regulatory approval, analyst says
The California-headquartered company said in September that it planned to acquire U.K.-based semiconductor firm Arm from Japanese conglomerate SoftBank.
CNBC.com · 11/19/2020 05:31
Chipmaker Nvidia could join tech's trillion-dollar club if Arm deal wins regulatory approval, analyst says
The California-headquartered company said in September that it planned to acquire U.K.-based semiconductor firm Arm from Japanese conglomerate SoftBank.
CNBC.com · 11/19/2020 05:31
Brokers Are Upgrading Their Views On Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) With These New Forecasts
Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) shareholders will have a reason to smile today, with the analysts making...
Simply Wall St. · 11/17/2020 04:10
Brokers Are Upgrading Their Views On Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) With These New Forecasts
Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) shareholders will have a reason to smile today, with the analysts making...
Simply Wall St. · 11/17/2020 04:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARMP. Analyze the recent business situations of Armata Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARMP stock price target is 7.25 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 119.54K
% Owned: 0.64%
Shares Outstanding: 18.70M
TypeInstitutionsShares
Increased
4
43.82K
New
0
0
Decreased
5
147.23K
Sold Out
13
36.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Non-Executive Chairman/Independent Director
Richard Bastiani
President
Brian Varnum
Chief Executive Officer/Director
Todd Patrick
Chief Financial Officer
Steven Martin
Vice President - Operations
Duane Morris
Vice President
Mina Pastagia
Other
Heather Jones
Director
Robin Kramer
Independent Director
Odysseas Kostas
Independent Director
Joseph Patti
Independent Director
Todd Peterson
Independent Director
Sarah Schlesinger
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARMP
Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.
More

Webull offers kinds of Armata Pharmaceuticals Inc stock information, including AMEX:ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARMP stock methods without spending real money on the virtual paper trading platform.